Although Dasatinib (Src-inhibitor) and taxane compounds have proven to be effective in combination therapy of other advanced cancers, such as NSCLC, the phase III clinical trial concluded that Dasatinib (Src inhibitor) failed to improve patient outcomes when combined with Docetaxel/Prednisone in advanced CRPC patients. This evidence concerns the gene SRC and cancer.